Loading…
HLN
Haleon plc
NYSE· Healthcare· Drug Manufacturers - Specialty & Generic· CUSIP 405552100
$10.37+3.49%Price as of Oct 23, 00:49 UTC · updated once a day, after the close
At a glance
Haleon plc (HLN) is listed on NYSE and classified in Drug Manufacturers - Specialty & Generic, part of the Healthcare sector. It is headquartered in Weybridge, United Kingdom and has 24,535 employees. The company is worth $45.6B and trades at 21.2x its earnings of the last twelve months; the median for its sector is 24.3x. Revenue was £11.03B in fiscal 2025, down 1.8% from the year before. Net income was £1.67B. The share price is 8.1% below its 52-week high of $11.28. It pays a dividend yielding 1.93%. 6 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Steve Cohen (Point72 Asset Management), at $86.44M. In that quarter, 5 of them opened or added to the position. No open-market insider trades in it were filed over the last 30 days.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Key metrics
- Market cap
- $45.6B
- P/E
- 21.2x
- Forward P/E
- 16.8x
- P/B
- 2.1x
- Dividend yield
- 1.93%
- Payout
- 40.82%
- EPS
- $0.49
- ROE
- 10.09%
- Profit margin
- 14.55%
- Revenue growth
- +2.20%
- Beta
- 0.28
- 52-week high
- $11.28
- 52-week low
- $8.65
History
Year by year, from the annual reports; dividends from the payments themselves.
Revenue, debt and profit are in GBP, the currency the company reports in — not converted to dollars. Dividends are in dollars.
Bars are year-end balances; lines are what happened during the year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▲ +44.1% over 5Y.
This stock has less than 5 years of price history — the answer would measure a shorter period than the one asked for.
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 4 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $10.11 | $9.54 | $8.23 | $8.00 | |
| EPS | £0.37 | £0.31 | £0.23 | £0.23 | |
| Dividend yield | 1.65% | 1.74% | 1.65% | 1.26% | — |
| Profit margin | 11.30% | 15.11% | 12.84% | 9.28% | 9.76% |
| ROE | 7.71% | 10.15% | 8.92% |
Fair price, seven ways
Seven formulas applied to the reported numbers, each with its assumption next to the result. None of them predicts a price.
Earnings
$7.38
Square root of 22.5 × earnings × book value. Blind to intangibles, so it undervalues software and brands.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Earnings
$11.90
Median P/E of 24.3 among peers in the sector.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Cash flow
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Operating
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Dividends
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| IQVIqvia Holdings Inc | $278.32 | 34.4x | 7.4x | 0.00% | 22.82% | $45.81B |
| WATWaters Corp | $455.59 | 115.9x | 2.9x | 0.00% | 1.92% | $44.73B |
| IDXXIdexx Laboratories Inc | $566.76 | 39.8x | 27.7x | 0.00% | 74.21% | $44.65B |
| TEVATEVA Pharmaceutical Industries Ltd | $40.21 |
About the company
- 24,535
- Weybridge, United Kingdom
